Amgen shared a post on LinkedIn:
“What if you could lock disease biology into place?
Amgen scientists are pioneering a potential new way to treat disease with LOCKTAC molecular glues that lock proteins together to control biological activity.
AMG 193 is one example of a LOCKTAC glue that is designed to selectively target tumor cells that have lost a gene called MTAP, with the goal of sparing healthy tissue. This potential first-in-class molecule is now in clinical trials.
Amgen’s innovative approach is now featured in Science Magazine. Read more about how Amgen is innovating in this space.”
More posts featuring Amgen.